Unfortunately, many patients suffer from an incomplete response to anti-VEGF therapy [14] and because these do not address the underlying degeneration of AMD, the disease is simply delayed, and there is recurrence when treatment is discontinued [15,16]. Here, VEGFA is linked to age-related macular degeneration.